https://orcid.org/0000-0001-7922-1209
References
- Chan RJ , Feng G-S . PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109(3), 862–867 (2007).
- Song Y , Zhao M , Wu Y , Yu B , Liu HM . A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors. Acta Pharm. Sin. B. 11(3), 750–762 (2021).
- Tang K , Wang S , Gao W , Song Y , Yu B . Harnessing the cyclization strategy for new drug discovery. Acta Pharm. Sin. B. 12(12), 4309–4326 (2022).
- Song Y , Zhao M , Zhang H , Yu B . Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacol. Ther. 230, 107966 (2022).
- Liu Y , Yang X , Wang Y et al. Targeting SHP2 as a therapeutic strategy for inflammatory diseases. Eur. J. Med. Chem. 214, 113264 (2021).
- Song Y , Yang X , Wang S , Zhao M , Yu B . Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery. Med. Res. Rev. 42(5), 1781–1821 (2022).
- Song Y , Wang S , Zhao M , Yang X , Yu B . Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy. J. Med. Chem. 65(4), 3066–3079 (2022).
- Song Z , Wang M , Ge Y et al. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. Acta Pharm. Sin. B. 11(1), 13–29 (2021).
- Zhang H , Yang X , Song Y , Yu B . Combining EGFR inhibitors with SHP2 or LSD1 inhibitors to overcome multidrug resistance in cancer. Future Med. Chem. 14(8), 527–529 (2022).
- Tang K , Jia YN , Yu B , Liu HM . Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders. Eur. J. Med. Chem. 204, 112657 (2020).
- Tang K , Zhao M , Wu YH et al. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors. Eur. J. Med. Chem. 230, 114106 (2022).
- Fan Z , Tian Y , Chen Z et al. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. EMBO mol. med. 12(6), e11571 (2020).
- Sha F , Gencer EB , Georgeon S et al. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. Proc. Natl Acad. Sci. USA 110(37), 14924–14929 (2013).
- Bobone S , Pannone L , Biondi B et al. Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions. J. Med. Chem. 64(21), 15973–15990 (2021).
- Guo W , Xu Q . Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds. J. Pharmacol. Sci. 144(3), 139–146 (2020).
- Song Y , Yu B . Targeting SHP2 for Cancer Treatment: Advances and Prospects. In: Handbook of Cancer and Immunology. Rezaei N ( Ed.). Springer International Publishing, Cham, Germany, 1–19 (2022).
- Liu M , Gao S , Liang T et al. Discovery of novel Src homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor immunity. J. Med. Chem. 65(18), 12200–12218 (2022).
- Liu Z , Liu Y , Qian L et al. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol. Cell 81(19), 4076–4090 (2021).